Best of ASCO - 2014 Annual Meeting

 

Welcome

Local-Regional

Genitourinary (Prostate) Cancer

2019 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
30-year extrapolations of overall survival (OS) and metastasis-free survival (MFS) from the SPCG-4 trial of radical prostatectomy (RP) versus watchful waiting (WW) in patients (pts) with early prostate cancer (ePCa).

Neda Alrawashdh

e16597

Assessment of 2,000 patients presenting to a multidisciplinary prostate cancer clinic in the United Kingdom.

Pandora Rudd

5077

Automated prostate lesion detection and PI-RADS assessment with deep learning.

Choongheon Yoon

e16605

CALGB 90203 (Alliance): Radical prostatectomy (RP) with or without neoadjuvant chemohormonal therapy (CHT) in men with clinically localized, high-risk prostate cancer (CLHRPC).

James Andrew Eastham

5079

Clinical and safety outcomes of TALAPRO-2: A two-part phase III study of talazoparib (TALA) in combination with enzalutamide (ENZA) in metastatic castration-resistant prostate cancer (mCRPC).

Neeraj Agarwal

5076

Comparative effectiveness of surgery versus external beam radiation with/without brachytherapy in intermediate and high-risk localized prostate cancer.

Ming Yin

e16602

Contemporary trends in treatment for low-risk prostate cancer.

Jason Frankel

5082

Deep learning hybrid 3D/2D convolutional neural network for prostate MRI recognition.

Jasper Van

e16600

Evaluation of the patient-reported outcomes common terminology criteria for adverse events (PRO-CTCAE) with abiraterone acetate plus prednisone (AAP), degarelix (D), or the combination in men with biochemically recurrent prostate cancer (BCRPC).

Karen A. Autio

5080

Human prostate cancer immune phenotypes after androgen deprivation therapy.

Matthew Dallos

5083

IMRT pelvic radiotherapy with simultaneous integrated boost in high-risk prostate cancer: Results after 10 years.

Christian Ekanger

5084

Multiparametric magnetic resonance imaging (mpMRI) and PSA density for the prediction of reclassification among patients under active surveillance.

Públio Viana

e16606

Prognostic impact of tristetraprolin (TTP) and PTEN loss and assessment of associated immune infiltrates in localized prostate cancer (PrCa).

Anis Hamid

e16601

Prospective head-to-head comparative phase 3 study between 18F-fluciclovine and 68Ga-PSMA-11 PET/CT in patients with early biochemical recurrence of prostate cancer.

Jeremie Calais

5014

Prostate image-guided transperineal elastic-registration biopsy, a new diagnostic tool to refine the risk-stratification of prostate cancer and improve therapeutic decisions.

Pierre Graff-Cailleaud

e16595

PROTEUS: A randomized, double-blind, placebo (PBO)-controlled, phase 3 trial of apalutamide (APA) plus androgen deprivation therapy (ADT) versus PBO plus ADT prior to radical prostatectomy (RP) in patients with localized high-risk or locally advanced prostate cancer (PC).

Mary-Ellen Taplin

TPS5100

Randomized phase II trial of presurgical androgen deprivation therapy (ADT) with or without axitinib in prostate cancer (PCa) presenting with lymph node (LN) metastasis.

Amado J. Zurita

5078

Randomized prospective phase 3 trial of 68Ga-PSMA-11 PET/CT molecular imaging for prostate cancer salvage radiotherapy planning [PSMA-SRT].

Jeremie Calais

TPS5101

Shifting patterns of care in localized prostate cancer: Impact on patient reported outcome measures (PROMs).

Brendan James Connell

e16603

Targeting backdoor androgen synthesis through AKR1C3 inhibition: A presurgical hormonal ablative trial in high risk localized prostate cancer (PC).

Laura Graham

5081

Ten year treatment complication outcomes of radical prostatectomy versus external beam radiation therapy versus brachytherapy for 1,503 patients with intermediate risk prostate cancer.

Barry W. Goy

e16599

The impact of simultaneous dose escalation VMAT to the focal lesion micro boost of localized prostate cancer.

Radwa Fawzy Saleh Ahmed

e16592

The internet bias toward nontraditional first line prostate cancer treatments.

Danny Landau

e16594

The relative contributions of the Genomic Prostate Score and comorbidity profile in predicting outcomes in surgically treated men with clinically low and intermediate-risk prostate cancer.

Jennifer Cullen

e16607